Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016613 · ClinicalTrials.gov registry record
Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
A clinical trial of Chronic Kidney Disease and Glomerulopathy, sponsored by University of Michigan.
- Recruiting
- Registry status
- 1,800
- Enrollment target
- 5
- Study locations
NCT01016613 is a study of Chronic Kidney Disease and Glomerulopathy that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 1,800 participants, below the 3,189-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (44% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT01016613, a study of Chronic Kidney Disease and Glomerulopathy, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- 1,800 participants
- Enrollment target
- 5
- Study locations
Study Summary
Chronic kidney disease (CKD) affects approximately 26 million Americans and disproportionately manifests in specific race and ethnic groups. Patients burdened with CKD have significant morbidity and reduced life expectancy. In addition to excessive suffering and lost productivity, the cost of managing this epidemic has reached $40 billion annually. The recognition that CKD is a major public health problem is reflected in the fourteen objectives outlined in Healthy People 2020 to begin to address the disease burden. Advancement in approaches to halt CKD progression has been slow despite growing global awareness of disease burden. This O'Brien Kidney Research Core will create opportunities for novel insights through characterization of tissue profiles that will define new disease markers and molecular pathways and will be available to all kidney investigators on the www. It will thereby fundamentally alter the starting point for research into prevention of progression of these kidney diseases. C-PROBE is an essential element of the center grant and presents a biomedical resource core consisting of: (1) clinical phenotyping (that is, systematic identification of observable physical and biomedical characteristics) of kidney disease patients including the accurate measurement of kidney function; and (2) a specimen BioBank which will store blood, urine and kidney tissue samples. A key component of C-PROBE is therefore that it contains a proven mechanism to collect samples from high risk groups including minorities, at the institutions of University of Michigan Health System, St. John Hospital, Wayne State University in Michigan, John H. Stroger Hospital in Illinois, Temple University Health System in Pennsylvania, and Levine Children's Hospital in North Carolina. This mechanism will feed the other Cores and provide biomedical investigators with approved projects the access to a dynamic pool of well characterized high risk kidney disease patients and their biological spec
Conditions Studied
Study Locations (5)
Michigan
- University of Michigan Health System - Ann Arbor
- Wayne State University - Detroit
- St. John's Health System - Detroit
North Carolina
- Levine Children's Hospital - Charlotte
Pennsylvania
- Temple University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2009-01 |
| Est. Completion | 2030-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01016613
The ClinicalTrials.gov registry entry for NCT01016613 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,189-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (44% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01016613 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Michigan, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01016613 about?
NCT01016613 is a clinical study titled "Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center". Chronic kidney disease (CKD) affects approximately 26 million Americans and disproportionately manifests in specific race and ethnic groups. Patients burdened with CKD have significant morbidity and reduced life expectancy. In addition to excessive suffering and lost productivity, the cost of managi...
What is the current status of trial NCT01016613?
This trial is currently recruiting. The enrollment target is 1,800 participants. The study started on 2009-01. Estimated completion is 2030-07.
What conditions does trial NCT01016613 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Glomerulopathy.
Who is sponsoring clinical trial NCT01016613?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01016613 being conducted?
This trial has 5 study locations across Michigan, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
RECRUITING · Phase 2
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
RECRUITING · Phase 4
-
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.